Posted On: 08/30/2014 5:34:03 AM
Post# of 9137
Mach, thanks for your clear and insightful analysis. What is absolutely transparent is that the current stock price is extremely discounted at $0.10.
According to the expert opinion of Dr. Sebastian Faro, there is nothing on the market that is better than the N-Assay.
Based on Mach's analysis of the N-Assay capturing 20% of the market in two years, beachlover12's net earnings number of $120m and extrapolating shares outstanding to be ~135m, how much would a potential buyout candidate be willing to today pay for just the N-Assay IP?
Currently, at $0.10, the market value of Nanologix is ~$13m. A company could offer $120m for the company and make all its money back in two years! That comes out to $0.92 per share. Remember that this is just for 20% of the GBS market. What company wouldn't love to make an investment that is paid off in just 2 years with years of exponentially growing profit ahead from all the other bacteria? Just another way to look at things....
Since there is nothing else better or cheaper, I don't see why the product wouldn't sell itself with perhaps a little nudge from the right type of lawyers. Hence, I must emphasize Mach's point that the company will likely need to look into subcontracting out the production of the N-Assay if it already isn't doing so. Otherwise, I doubt the company will able to keep up with the demand.
How exciting would it be if such an agreement were announced? This would be a great catalyst as it would imply lots of new future revenues. BIG multiples to earnings are given to companies with such avenues of growth (i.e., Tesla with a forward PE of 81.23 due to their expected growth in revenue streams in China). Who knows? This could be what breaks the manipulator's control of NNLX stock.
According to the expert opinion of Dr. Sebastian Faro, there is nothing on the market that is better than the N-Assay.
Based on Mach's analysis of the N-Assay capturing 20% of the market in two years, beachlover12's net earnings number of $120m and extrapolating shares outstanding to be ~135m, how much would a potential buyout candidate be willing to today pay for just the N-Assay IP?
Currently, at $0.10, the market value of Nanologix is ~$13m. A company could offer $120m for the company and make all its money back in two years! That comes out to $0.92 per share. Remember that this is just for 20% of the GBS market. What company wouldn't love to make an investment that is paid off in just 2 years with years of exponentially growing profit ahead from all the other bacteria? Just another way to look at things....
Since there is nothing else better or cheaper, I don't see why the product wouldn't sell itself with perhaps a little nudge from the right type of lawyers. Hence, I must emphasize Mach's point that the company will likely need to look into subcontracting out the production of the N-Assay if it already isn't doing so. Otherwise, I doubt the company will able to keep up with the demand.
How exciting would it be if such an agreement were announced? This would be a great catalyst as it would imply lots of new future revenues. BIG multiples to earnings are given to companies with such avenues of growth (i.e., Tesla with a forward PE of 81.23 due to their expected growth in revenue streams in China). Who knows? This could be what breaks the manipulator's control of NNLX stock.
(0)
(0)Scroll down for more posts ▼
